KFDA to set fast review standards for new BT products.

Published: 2006-04-11 06:58:00

Updated: 2006-04-11 06:58:00

To expedite rapid commercialization of the bio drugs, the health regulatory agency is going to establish a review standard and a supporting system, which may guide for the BT R&D to see its direction far in advance or aid for the BT researchers to monitor the research progress in advance through ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK